24 September 2024
24 September 2024
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
The approval sets up a showdown between Iqirvo and Intercept’s PBC treatment Ocaliva.
The FDA’s recommended dosage is 160mg bimekizumab administered via subcutaneous injection every four weeks.
New safety data shows an absence of post-injection syndrome, a rare and serious side effect of long-acting olanzapine.
The latest approval of FRUZAQLA is based on the outcomes of the international Phase III FRESCO-2 trial.
In a Phase III trial, almost 60% of subjects treated with Fasenra achieved remission.
The company has initiated a Phase I trial of its bivalent RSV and hMPV-targeting vaccine called VXB-241.
The authorisation for Anzupgo cream is supported by the Phase III DELTA 1 and DELTA 2 clinical trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
